Ai-enhanced in-vivo screening assay for CNS drug delivery systems
Nucleo Technologies introduces a novel in-vivo screening assay that leverages AI tools to enhance the development of CNS drug delivery systems (DDSs). This approach integrates AI design, yeast surface display, and proprietary quantification assays to optimize brain delivery efficiency.
Overview
Nucleo Technologies presents an advanced solution for accelerating the development of central nervous system (CNS) drug delivery systems (DDSs). By integrating cutting-edge AI tools, such as AlphaFold and diffusion models, with yeast surface display screening and a proprietary in-vivo quantification assay, this innovative platform aims to overcome the current limitations in DDS development. The approach significantly enhances the identification of effective DDSs, potentially surpassing existing solutions by targeting numerous blood-brain barrier-specific receptors. This method is particularly beneficial for developing DDSs that can deliver oligonucleotide drugs efficiently to the brain.
Technical specifications
- AI-Driven Design: Utilizes 3D structure modeling of five conserved human/murine Receptor Mediated Transcytosis (RMT) proteins for predicting single-domain antibody (sdAb) binders.
- Yeast Surface Display: sdAb libraries are expressed in yeast and screened against human and murine cell-presented targets to identify top binders.
- In-Vivo Quantification: The top 100 binders are modified and tested in live mice using a proprietary platform to assess brain delivery efficiency.
- Therapeutic Proof of Concept: Promising carriers are conjugated with oligonucleotides to evaluate brain distribution via immunohistochemistry.
Technology readiness level
This technology is currently at Technology Readiness Level 5, indicating that the solution has been validated in a relevant environment and is progressing towards further refinement and potential commercialization.
About Nucleo Technologies INC
NucleoTech is a biotechnology company focused on advancing drug delivery systems to treat brain-related conditions. The company engineers proprietary carriers called BrainPortal, which are proteins designed to attach to therapeutic antibodies and oligonucleotides. By leveraging these carriers, NucleoTech enables therapeutics to cross the blood-brain barrier safely and non-invasively, addressing the physical barrier that prevents approximately 98% of drugs from reaching their targets in the brain. The company utilizes a direct in vivo screening platform that allows for the simultaneous testing of numerous carriers in living animals, significantly increasing the throughput and speed of discovery compared to conventional linear methods.
This technology is intended to overcome the significant limitations in treating complex neurological disorders, including neurodegeneration, brain cancers, and mental health conditions. By providing a scalable and efficient path for drug delivery, NucleoTech aims to advance its own internal CNS therapeutic pipeline and support pharma and biotech partners through licensing programs for its carrier portfolio. The company's approach removes the need for surgical intervention or complex drug reformulation, offering a pathway to bring previously blocked treatments to patients suffering from leading causes of disability and death worldwide.
delivered to your inbox.